Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha lipoic acid + gabapentin + methylcobalamin
- Development stage
- Unknown
- Lead developer
- SSK Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AXOFIT-G100 is an oral fixed-dose combination of gabapentin, methylcobalamin, and alpha lipoic acid developed by SSK Pharma. It is approved and marketed in India for the treatment of neuropathic pain, such as diabetic neuropathy and post-herpetic neuralgia. Gabapentin acts as an anticonvulsant and analgesic by binding to the alpha-2-delta subunits of voltage-gated calcium channels, thereby reducing the release of excitatory neurotransmitters. Methylcobalamin, an active form of vitamin B12, serves as a cofactor for methionine synthase, promoting myelin sheath regeneration and nerve repair. Alpha lipoic acid is a potent antioxidant and mitochondrial cofactor that mitigates oxidative stress and improves nerve conduction. Together, these components provide synergistic relief from neuropathic pain and support nerve health.
- Brand names
- AlfagabaAxofit-GAxofit-G 300Axofit-G300Axofit-G-300Axofit-G100Axofit-G-100Axofit-G 100Gabagesic PlusGabapin PlusTrigabantin
- Other names
- Gabapentin + methylcobalamin + alpha lipoic acidMethylcobalamin + gabapentin + alpha lipoic acid
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (Voltage-gated calcium channel subunit alpha-2/delta-2)MTR (Methionine synthase)PDH (Pyruvate dehydrogenase complex)CACNA2D2 (α2δ-2)
Beyond the preview
Go deeper on alpha lipoic acid + gabapentin + methylcobalamin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha lipoic acid + gabapentin + methylcobalamin.